Industrial Development Administration, Ministry of Economic Affairs
Innovative Medical Products Market-Access Value-Enhancement Program
創新醫療產品市場准入價值推升計畫
Subsidy ceilingUp to NT$6.0M (~NT$6,000,000)
Industry chapter12 · Consumer Goods & Chemical Industries
Eligibility
ROC-registered companies in good credit standing — manufacturers that hold or contract to PIC/S GMP-certified facilities in Taiwan.
What’s offered
End-to-end medical-product market access: drives domestic adoption, runs clinical-validation projects (including digital-health), provides feasibility advisory, connects products to Taiwan hospitals for clinical trials, and supports international rollout via overseas-field linkage.
Key terms
- Feasibility advisory
- Company self-funded portion capped at NT$1,500,000.
- Domestic hospital matching
- Government subsidy capped at NT$4,500,000.
- Clinical-trial design evaluation
- Requires complete documentation plus a clinically demonstrable trial design.
- Product-integration self-funding
- Capped at NT$2,000,000.
- Field-build government subsidy
- Capped at NT$6,000,000.
Program structure
Drive domestic adoption — strengthen clinical validation
- Feasibility advisory
- Connect to domestic medical institutions
- Clinical-trial design evaluation
- End-to-end advisory linking innovative product manufacturers with hospitals to test product effectiveness, run clinical-effect validation, complete sound clinical-trial designs, and prepare a clinical-validation report.
Overseas field linkage — accelerate international rollout
- Product integration
- Field deployment
- Clinical validation
- Integrates one or more products into a smart medical (SaMD) overseas package — introduces Taiwanese medical-device solutions onto international platforms.
Application window
Per official announcement each cycle.
Who to contact
ITRI Industry Medical Electronics Promotion Office
財團法人人工智慧技術研究院產業醫療電子化推動辦公室
English-language application support: not confirmed. Plan to bring a Mandarin-fluent collaborator to the first conversation.